Retatrutide (5mg – 100mg)

Retatrutide is a synthetic triple receptor agonist targeting GLP-1, GIP, and glucagon pathways, supplied as a lyophilized powder for in-vitro laboratory research use. Purity specification: above 99% (HPLC-MS). Supplied as a stable lyophilized powder for in-vitro laboratory research use only.

Retatrutide (5mg – 100mg) serves as a research tool for examining the interplay between peptide signaling and metabolic endpoints in experimental designs.

Laboratory programs frequently validate Retatrutide (5mg – 100mg) with HPLC purity checks and mass confirmation before assay work begins.

Retatrutide (5mg – 100mg) is commonly included in metabolic research panels investigating appetite-regulating pathways and energy homeostasis in laboratory models.

This product is available in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg and 100mg. Each vial contains lyophilized peptide at the labeled quantity; wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only —not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Retatrutide (5mg – 100mg). Summaries are provided for orientation only and reflect the cited sources.

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial^[1] —This double-blind, randomized phase 3 trial (TRANSCEND-T2D-1) evaluated the efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes who had inadequate glycaemic control with diet and exercise. The authors assessed glycaemic outcomes and adverse events across treatment groups. The results indicated that retatrutide may offer benefits for glycaemic control in this population. (Lancet (London, England) 2026)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial^[2] —This randomized phase 2a trial investigated the triple hormone receptor agonist retatrutide in people with metabolic dysfunction-associated steatotic liver disease. The authors examined markers of liver fat and metabolic status after treatment. The findings suggested that retatrutide may reduce liver fat and improve metabolic parameters in this condition. (Nature medicine 2024)

The power of three: Retatrutide's role in modern obesity and diabetes therapy^[3] —This review discusses the role of retatrutide in modern obesity and diabetes therapy, focusing on its combined agonism at GIP, GLP-1, and glucagon receptors. The authors examine how this triple receptor profile may translate into enhanced weight loss and metabolic benefits. They consider the potential and the open questions surrounding this investigational therapy. (European journal of pharmacology 2024)

Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes^[4] —This study analyzed changes in cardiovascular risk biomarkers associated with retatrutide treatment in adults with obesity, with or without type 2 diabetes. The authors examined biomarker changes across treatment groups during the study. The results indicated that retatrutide may improve certain cardiovascular risk biomarkers in this population. (Diabetes, obesity & metabolism 2026)

References

1. Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." Lancet (London, England). 2026. pubmed.ncbi.nlm.nih.gov/42250575/
2. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nature medicine. 2024. pubmed.ncbi.nlm.nih.gov/38858523/
3. Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood A. "The power of three: Retatrutide's role in modern obesity and diabetes therapy." European journal of pharmacology. 2024. pubmed.ncbi.nlm.nih.gov/39515565/
4. Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ. "Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes." Diabetes, obesity & metabolism. 2026. pubmed.ncbi.nlm.nih.gov/42608321/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.